

BIOCRYST PHARMACEUTICALS INC

Form 8-K

October 11, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 5, 2011

BioCryst Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction

of incorporation)

000-23186
(Commission

File Number)

62-1413174
(IRS Employer

Identification No.)

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 8-K

4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703

(Address of Principal Executive Offices) (Zip Code)

(Registrant's telephone number, including area code): (919) 859-1302

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 5, 2011, the Board of Directors of BioCryst Pharmaceuticals, Inc. (the "Company") elected George B. Abercrombie to the Company's Board of Directors, effective October 10, 2011. Also on October 5, 2011, Stephen R. Biggar, M.D., Ph.D, tendered his resignation from the Board of Directors, effective October 10, 2011. The Company issued a news release reporting these matters on October 11, 2011, and a copy of the news release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The Company's Board of Directors has not yet appointed Mr. Abercrombie to serve on any of its committees. Dr. Biggar has served on the Compensation and Corporate Governance and Nominating Committees of the Company's Board of Directors.

Pursuant to the Company's Stock Incentive Plan, Mr. Abercrombie will receive an automatic grant of 16,667 stock options upon election, and will be entitled to a grant of 15,000 stock options after each annual stockholders' meeting. Mr. Abercrombie will receive compensation consistent with the Company's director compensation policy as described in the Company's proxy statement for its 2011 annual meeting of stockholders.

Item 7.01 Regulation FD Disclosure

The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein.

The information furnished is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press release dated October 11, 2011 entitled "BioCryst Pharmaceuticals Announces Changes to its Board of Directors"

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BioCryst Pharmaceuticals, Inc.

By: /s/ Alane Barnes

Name: Alane Barnes

Title: General Counsel, Corporate Secretary

Date: October 11, 2011

INDEX TO EXHIBITS

Exhibit No.	Description
99.1	Press release dated October 11, 2011 entitled BioCryst Pharmaceuticals Announces Changes to Its Board of Directors